SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02713880
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
International, multicenter, observational, longitudinal study to identify biomarker/s for the
development of a new MS-based biomarker for the early and sensitive diagnosis of
Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood and number of correctly
identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy
NCT02713880 Transthyretin Amyloidosis Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy Transthyretin Amyloid Cardiopathy
Primary Outcomes
Measure: Development of a new MS-based biomarker for the early and sensitive diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood Time: 36 months
Secondary Outcomes
Measure: Number of correctly identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy Time: 36 months
Time Perspective: Prospective
Cohort
There is one SNP
SNPs
Even though more than 100 point
mutations are known to cause the disease, the most common amino acid change is V30M. --- V30M ---